166 related articles for article (PubMed ID: 18077790)
1. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
Brown PJ; Ashe SL; Leich E; Burek C; Barrans S; Fenton JA; Jack AS; Pulford K; Rosenwald A; Banham AH
Blood; 2008 Mar; 111(5):2816-24. PubMed ID: 18077790
[TBL] [Abstract][Full Text] [Related]
2. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
3. N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
Brown PJ; Gascoyne DM; Lyne L; Spearman H; Felce SL; McFadden N; Chakravarty P; Barrans S; Lynham S; Calado DP; Ward M; Banham AH
Haematologica; 2016 Jul; 101(7):861-71. PubMed ID: 27056922
[TBL] [Abstract][Full Text] [Related]
4. The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.
van Keimpema M; Grüneberg LJ; Schilder-Tol EJ; Oud ME; Beuling EA; Hensbergen PJ; de Jong J; Pals ST; Spaargaren M
Haematologica; 2017 Mar; 102(3):573-583. PubMed ID: 27909217
[TBL] [Abstract][Full Text] [Related]
5. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
6. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
[TBL] [Abstract][Full Text] [Related]
7. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
8. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
[TBL] [Abstract][Full Text] [Related]
9. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma.
Courts C; Brunn A; Montesinos-Rongen M; Siemer D; Hans V; Paulus W; Wiestler OD; Küppers R; Siebert R; Deckert M
J Neuropathol Exp Neurol; 2009 Sep; 68(9):972-6. PubMed ID: 19680146
[TBL] [Abstract][Full Text] [Related]
10. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
Flori M; Schmid CA; Sumrall ET; Tzankov A; Law CW; Robinson MD; Müller A
Blood; 2016 Mar; 127(11):1438-48. PubMed ID: 26729899
[TBL] [Abstract][Full Text] [Related]
11. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
[TBL] [Abstract][Full Text] [Related]
12. Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1.
Rouhigharabaei L; Finalet Ferreiro J; Tousseyn T; van der Krogt JA; Put N; Haralambieva E; Graux C; Maes B; Vicente C; Vandenberghe P; Cools J; Wlodarska I
PLoS One; 2014; 9(1):e85851. PubMed ID: 24416450
[TBL] [Abstract][Full Text] [Related]
13. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
[TBL] [Abstract][Full Text] [Related]
14. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
16. Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.
Barrans SL; Fenton JA; Ventura R; Smith A; Banham AH; Jack AS
Haematologica; 2007 Jun; 92(6):863-4. PubMed ID: 17550867
[TBL] [Abstract][Full Text] [Related]
17. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.
Goatly A; Bacon CM; Nakamura S; Ye H; Kim I; Brown PJ; Ruskoné-Fourmestraux A; Cervera P; Streubel B; Banham AH; Du MQ
Mod Pathol; 2008 Jul; 21(7):902-11. PubMed ID: 18487996
[TBL] [Abstract][Full Text] [Related]
18. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations.
Wlodarska I; Veyt E; De Paepe P; Vandenberghe P; Nooijen P; Theate I; Michaux L; Sagaert X; Marynen P; Hagemeijer A; De Wolf-Peeters C
Leukemia; 2005 Aug; 19(8):1299-305. PubMed ID: 15944719
[TBL] [Abstract][Full Text] [Related]
19. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
Barrans SL; Fenton JA; Banham A; Owen RG; Jack AS
Blood; 2004 Nov; 104(9):2933-5. PubMed ID: 15238418
[TBL] [Abstract][Full Text] [Related]
20. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells.
van Keimpema M; Grüneberg LJ; Mokry M; van Boxtel R; Koster J; Coffer PJ; Pals ST; Spaargaren M
Blood; 2014 Nov; 124(23):3431-40. PubMed ID: 25267198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]